https://doi.org/10.1016/j.vaccine.2019.09.099
Our analysis included 14 Asian countries that were estimated to have a total of 850,000 choleracases and 25,500 deaths in 2015 While, the WHO cholera report documented around 60,000 cholera casesand 28 deaths. We estimated around $20.2 million (I$74.4 m...illion) in out-of-pocket expenditures, $8.5million (I$30.1 million) in public sector costs, and $12.1 million (I$43.7 million) in lost productivity in2015. Lost productivity due to premature deaths was estimated to be $985.7 million (I$3,638.6 million).Our scenario analyses excluding mortality costs showed that the economic burden ranged from 20.3%($8.3 million) to 139.3% ($57.1 million) in high and low scenarios when compared to the base case sce-nario ($41 million) and was least at 10.1% ($4.1 million) when estimated based on cholera cases reportedto WHO
more
Morbidity and Mortality Weekly Report (MMWR) October 4, 2019 / 68(39);851–854
DEPRESSION AND ANXIETY 27 : 390–403 (2010
Published OnlineNovember 13, 2018 http://dx.doi.org/10.1016/ S2468-2667(18)30238-X
International Journal for Quality in Health Care, 2018, 30(9), 724–730
Promoting hand hygiene in a neonatal intensive care unit.
The Lancet Published Online June 11, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30934-1
More than one-in-five people living in conflict-affected areas suffers from a mental illness, according to a new UN-backed report, prompting the World Health Organization (WHO) to call for increased, sustained... investment in mental health services in those zones.
Around 22 per cent of those affected, suffer depression, anxiety or post-traumatic stress disorder, according to this analysis.
The study also shows that about nine per cent of conflict-affected populations have a moderate to severe mental health condition; substantially higher than the global estimate for these mental health conditions in the general population.
more
DOI: 10.1126/science.aax2196; Science 08 Mar 2019: Vol. 363, Issue 6431, pp. 1017
Lancet Neurol. Volume 18, ISSUE 5, P439-458, May 01, 2019
Published Mar 11. pii: S1474-4422(19)30034-1. doi: 10.1016/S1474-4422(19)30034-1.
Lancet Neurol 2019 Volume 18, ISSUE 5, P459-480, May 01, 2019
Published OnlineMarch 14, 2019 http://dx.doi.org/10.1016/ S1474-4422(18)30499-X
Lancet Neurol. 2019 Apr;18(4):357-375. doi: 10.1016/S1474-4422(18)30454-X. Epub 2019 Feb 14.
Lancet Glob Health 2020; 8: e341–51
Francophone Africa still carries a high burden of communicable and neonatal diseases, probably due to the weakness of health-care systems and services, as evidenced by the almost complete attribution of DALYs to YLLs. To cope with this burden of disease, franco...phone Africa should define its priorities and invest more resources in health-system strengthening and in the quality and quantity of health-care services, especially in rural and remote areas. The region could also be prioritised in terms of technical and financial assistance focused on achieving these goals, as much as on demographic investments including education and family planning
more
Editorial| Volume 2, ISSUE 9, e415, September 01, 2021
TB situation in vulnerable populations. Rev. Nac. (Itauguá) vol.13 no.1 Itauguá jun. 2021
La pandemia de covid-19 ha afectado la detección y tratamiento de pacientes con TBC en Paraguay que lejos de ser una enfermedad erradicada, es motivo de preocupación sanitaria y sigue afectando a miles de ...personas, si bien se inician actividades de campo con apoyo del PNCT para la búsqueda activa, seguimiento de casos y control de contactos en comunidades indígenas y asentamientos, estas tareas no son continuas debido al aumento de los casos de covid-19 en el país, que favorece el temor a acudir a los hospitales para el diagnóstico, a sus controles e incluso se ve afectado el retiro de los medicamentos. En el marco de la pandemia, es probable que aumenten los fracasos terapéuticos con el consiguiente desenlace fatal, por lo que debe hacerse una revisión de las estrategias dirigidas a poblaciones vulnerables con un compromiso verdadero del sector político, sumado a una fuerte colaboración multisectorial e intercultural para lograr el fin de la TBC
more
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of... Buruli ulcer everywhere. However, this finding does not mean that
Buruli ulcer is cured at 8 weeks.
more
August 26, 2021
https://doi.org/10.1371/journal.pntd.0009678
Buruli ulcer caused by Mycobacterium ulcerans is a neglected tropical disease characterized by extensive ulceration involving predominantly the upper and lower limbs of patients. The disease is common in rural tropical communities in West and Central Africa, where access to proper health care is lim...ited. Pathogenesis of the characteristic painless ulcers is linked to the elaboration by M. ulcerans of a lipid toxin called mycolactone that has potent cytopathic, immunosuppressive, and analgesic effects on a host of cells in cutaneous tissues. Mycolactone is known to profoundly inhibit secretion of a plethora of proteins that are essential for wound healing. Even though a combination antibacterial therapy of streptomycin and rifampicin for 8 weeks is effective for treatment, it relies on good and appropriate wound management to prevent secondary bacterial infections and improve healing. Evidence-based interventions for wound care in Buruli ulcer disease are often lacking and have relied on expert advice and recommendations. Surgical interventions are limited to debridement of necrotic tissue and grafting of extensive ulcers, usually after antibiotic therapy. Patients’ rehabilitation is an important component of care to reduce disabilities associated with the disease and proper integration into the community after treatment.
more
Nat Commun 9, 5370 (2018). https://doi.org/10.1038/s41467-018-07804-8. Mycobacterium ulcerans is the causative agent of Buruli ulcer, a neglected tropical skin disease that is most commonly found in children from West and Central Africa. Despite the severity of the infection, therapeutic options are... limited to antibiotics with severe side effects. Here, we show that M. ulcerans is susceptible to the anti-tubercular drug Q203 and related compounds targeting the respiratory cytochrome bc1:aa3. While the cytochrome bc1:aa3 is the primary terminal oxidase in Mycobacterium tuberculosis, the presence of an alternate bd-type terminal oxidase limits the bactericidal and sterilizing potency of Q203 against this bacterium. M. ulcerans strains found in Buruli ulcer patients from Africa and Australia lost all alternate terminal electron acceptors and rely exclusively on the cytochrome bc1:aa3 to respire. As a result, Q203 is bactericidal at low dose against M. ulcerans replicating in vitro and in mice, making the drug a promising candidate for Buruli ulcer treatment.
more
Chikungunya virus (CHIKV) is currently one of the most relevant arboviruses to public health. It is a member of the Togaviridae family and alphavirus genus and causes an arthritogenic disease known as chikungunya fever (CHIKF). It is characterized by a multifaceted disease, which is distinguished fr...om other arbovirus infections by the intense and debilitating arthralgia that can last for months or years in some individuals. Despite the great social and economic burden caused by CHIKV infection, there is no vaccine or specific antiviral drugs currently available. Recent outbreaks have shown a change in the severity profile of the disease in which atypical and severe manifestation lead to hundreds of deaths, reinforcing the necessity to understand the replication and pathogenesis processes. CHIKF is a complex disease resultant from the infection of a plethora of cell types. Although there are several in vivo models for studying CHIKV infection, none of them reproduces integrally the disease signature observed in humans, which is a challenge for vaccine and drug development. Therefore, understanding the potentials and limitations of the state-of-the-art experimental models is imperative to advance in the field. In this context, the present review outlines the present knowledge on CHIKV epidemiology, replication, pathogenesis, and immunity and also brings a critical perspective on the current in vitro and in vivo state-of-the-art experimental models of CHIKF.
more